Expanded Access of Pimavanserin for Patients With PD Psychosis
NCT02762591 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2017-04-18
Summary
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
Conditions
- Parkinson's Disease Psychosis
Interventions
- DRUG
-
Pimavanserin tartrate
Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
Sponsors & Collaborators
-
ACADIA Pharmaceuticals Inc.
lead INDUSTRY
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
NCT04164758 ·Status: TERMINATED ·Phase: PHASE2
-
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT03947216 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
NCT06068465 ·Status: COMPLETED ·Phase: PHASE3
-
Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT06754553 ·Status: NOT_YET_RECRUITING
-
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
NCT04373317 ·Status: RECRUITING ·Phase: PHASE4
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
NCT02847650 ·Status: TERMINATED ·Phase: PHASE2
-
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
NCT01227265 ·Status: COMPLETED ·Phase: PHASE3
-
AAV2-hAADC for Parkinson's Disease (PDCS-01)
NCT07267065 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
ACP-103 to Treat Parkinson's Disease
NCT00086294 ·Status: COMPLETED ·Phase: PHASE2
-
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
NCT05357989 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
NCT02373072 ·Status: COMPLETED ·Phase: PHASE1
-
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
NCT06965374 ·Status: RECRUITING
-
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
NCT02006290 ·Status: COMPLETED ·Phase: PHASE1
-
Pimavanserin Treatment in TS
NCT04794413 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
NCT03665454 ·Status: COMPLETED ·Phase: PHASE1
-
SHARPEN - Parkinson's Disease Dementia
NCT05987540 ·Status: TERMINATED ·Phase: NA
-
Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
NCT04810104 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
NCT00397696 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease
NCT00627588 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
D-serine Adjuvant Treatment for Parkinson's Disease
NCT00215904 ·Status: COMPLETED ·Phase: PHASE4
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
NCT03149809 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
NCT02601586 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.
NCT04273932 ·Status: COMPLETED ·Phase: PHASE1
-
Lithium for Parkinson's: an Extension Trial
NCT06592014 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2